Predictive DNA-testing for Huntington's disease and reproductive decision making: a European collaborative study.
This European collaborative study addresses the question whether a predictive test result for Huntington's disease (HD) has an effect on subsequent reproduction by comparing carriers and non-carriers of the Huntington mutation. A unique characteristic of this study is that this evaluation is done in persons at reproductive age who had a predictive test after the identification of the Huntington gene and who were counselled in one of the participating centres. Data were collected for 180 carriers and 271 non-carriers who received a predictive test result in the period 1993-1998 in Aberdeen, Athens, Cardiff, Leiden, Leuven, Paris or Rome. The mean age of the total study group was 31.5 years and for about half of the group the follow-up interval was 3 years or more, with a maximum of 7 years. The collaborative study clearly revealed an overall impact of the predictive test result on subsequent reproduction: 14% of the carriers had one or more subsequent pregnancies vs 28% of the non-carriers. In the total carrier group a prenatal test was carried out in about two thirds of the pregnancies and one child was born after preimplantation genetic diagnosis; artificial insemination by donor, egg cell donation or adoption were not reported. A more refined analysis was performed in the subgroup with a follow-up interval of at least 3 years and who reported 'family planning' as a motive to apply for predictive testing in the pretest period. The complexity of this motive is discussed. In this subgroup with a desire for children in the pretest period the effect of the predictive test result was more pronounced: 69% of the non-carriers had subsequent pregnancies while only 39% of the carriers who mentioned 'family planning' as one of the major reasons to apply for predictive testing had a subsequent pregnancy. Of the carriers with one or more subsequent pregnancies the percentage using prenatal diagnosis was slightly higher than the percentage not using it, although there were clear differences from one centre to another. The latter group's decisions may seem more intriguing but may be partially understood based on stage theories of health behaviour. Last, but not least, whatever option is chosen by a couple at increased risk of transmitting the Huntington mutation, it is of the utmost importance that professionals fully respect this decision and support the couple.
Evers-Kiebooms
Gerry
G
Psychosocial Genetics Unit, Center for Human Genetics, K.U. Leuven, Leuven, Belgium. Gerry.Kiebooms@med.kuleuven.ac.be
Nys
Kurt
K
Harper
Peter
P
Zoeteweij
Moniek
M
Dürr
Alexandra
A
Jacopini
Gioia
G
Yapijakis
Christos
C
Simpson
Sheila
S
D000328:Adult; D000367:Age Factors; D005060:Europe; D005193:Family Planning Services; D005817:Genetic Counseling; D005820:Genetic Testing / Q000592:standards*; D006579:Heterozygote; D006801:Humans; D006816:Huntington Disease / Q000235:genetics*; D009154:Mutation; D011296:Prenatal Diagnosis